癌胚抗原(Carcinoembryonic antigen,简称CEA)系1965年由Gold和Freedman从结肠腺癌中提出。测定CEA的主要价值据称可诊断消化道肿瘤。以后的研究显示血循环中CEA浓度增加也可存在于各种良性病变,特别是肝病中,因而就限制了该试验的特异性。最近实验提示,临床上根据CEA浓度来评价癌肿预后和疗效时要考虑肝功能状态。 Carcinoembryonic antigen (CEA) was proposed by Gold and Freedman from colon adenocarcinoma in 1965. The main value of CEA is claimed to diagnose digestive tract tumors. Subsequent studies have shown that increased concentrations of CEA in the blood circulation can also be present in various benign lesions, especially in liver disease, thereby limiting the specificity of this test. Recent experiments suggest that clinically based on CEA concentration to evaluate the prognosis and efficacy of cancer to consider the state of liver function.